PLUVICTO Targeting PSMA Biomarker in Prostate Cancer Cell

Radiation Center of Greater Nashua now offering PLUVICTO® for advanced prostate cancer

Community-based radioligand therapy brings an important targeted treatment closer to eligible patients and families

NASHUA, N.H. – The Radiation Center of Greater Nashua (RCGN) is now offering PLUVICTO® (lutetium Lu 177 vipivotide tetraxetan), an FDA-approved targeted radioligand therapy for certain adults with advanced prostate cancer. The community-based program gives eligible patients access to this specialized treatment closer to home, reducing the need for repeated travel to a distant hospital or academic medical center.

PLUVICTO is used for adults with prostate-specific membrane antigen-positive metastatic prostate cancer, known as mHSPC. It may be an option for certain patients whose prostate cancer has continued to grow during hormone-based treatment (androgen receptor pathway inhibitor and androgen receptor therapy).

PLUVICTO is available to be used across all stages of PSMA+ metastatic prostate cancer. PLUVICTO is the only PSMA-targeted agent FDA approved for metastatic prostate cancer.

Eligibility is determined individually by qualified clinicians using an approved PSMA PET scan, treatment history, laboratory results and overall health.

“For patients living with advanced prostate cancer, time at home and time with family matter. Offering PLUVICTO in Nashua gives eligible patients access to a new innovative treatment option while keeping their care connected to the physicians and support systems they already know.” said Stephen Harris, M.D., Medical Director at RCGN.

Meeting a need close to home

Prostate cancer affects hundreds of families in Southern New Hampshire each year. National Cancer Institute and Centers for Disease Control and Prevention data show that New Hampshire averaged approximately 1,230 new prostate cancer diagnoses annually from 2018 through 2022. Nationally, the American Cancer Association estimates 333,830 new Prostate cancer diagnosis in 2026 and now has surpassed Breast cancer as the number one diagnosed cancer in the United States.

Nationally, about 8.5% of prostate cancers are diagnosed after spreading to distant parts of the body, and five-year relative survival for distant-stage disease is about 40%. These figures underscore the importance of expanded treatment options and convenient access to specialized care.

How PLUVICTO works

PLUVICTO works like a targeted delivery system. One part of the medicine seeks out PSMA, a protein commonly found on prostate cancer cells. Another part carries a small amount of radiation directly to those cells and nearby tissue. The medicine is given through a vein and circulates through the body, allowing it to reach PSMA-positive cancer cells in different locations.

Treatment is generally administered once every six weeks for up to six doses, depending on response and tolerability. Before each treatment, the care team reviews blood counts, kidney function, symptoms and other clinical information. Patients receive individualized instructions about hydration, radiation precautions, laboratory monitoring and follow-up care.

Coordinated care with safety at every step

RCGN’s program combines the detailed safety framework of a radiopharmaceutical service with the personal coordination of community cancer care.

Physicians, nurses, medical physicists, radiation therapists, radiation-safety personnel, administrative staff and referring oncology teams work together throughout the process. Local treatment may also simplify laboratory testing, symptom management, follow-up visits and communication among a patient’s medical oncologist, urologist and radiation oncologist.

“We want patients to feel informed, supported and safe at every step. Bringing this care to Nashua means fewer miles on the road, easier coordination with local doctors and more time for patients to focus on their health and the people who matter most.” said Charles Mangano, Clinical Director at RCGN.

Information for patients and referring clinicians

Patients interested in learning more should speak with the physician(s) managing their prostate cancer or call RCGN at 603-880-1590. Referring clinicians may use the same number for program information and referral assistance

References:

Similar Posts